Ot­su­ka’s $886M-plus drug just flopped in its first cru­cial PhI­II tri­al for front­line AML

Five years ago Ot­su­ka swept in and scooped up Cal­i­for­nia-based As­tex for $886 mil­lion, de­ter­mined to get its hands on their promis­ing leukemia drug SGI-110 as it plugged the op­er­a­tions in­to its glob­al R&D ops. Now the drug is called guadecitabine, and it just flopped in the first piv­otal Phase III study, crash­ing co-pri­ma­ry end­points for com­plete re­spons­es and over­all sur­vival for front­line use among ad­vanced pa­tients with acute myeloid leukemia.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER